Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | CRHR1 | P34998 | 10/20 | 0.34 |
| ▸ | TAS1R3 | Q7RTX0 | 4/20 | 0.34 |
| ▸ | TAS1R1 | Q7RTX1 | 4/20 | 0.34 |
| ▸ | PTGES | O14684 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3102377 | 0.86 | KDM4E (0.36) | MAPTTAS1R3TAS1R1 | |
| SCHEMBL3098641 | 0.85 | CA12 (0.40) | POLBMAPTHPGDTSHRHSD17B10 | |
| SCHEMBL3091435 | 0.84 | EGFR (0.44) | POLBMAPTHPGDHSD17B10 | |
| SCHEMBL3101023 | 0.81 | SMN1; SMN2 (0.42) | MAPTHPGDTSHRHSD17B10 | |
| SCHEMBL3106697 | 0.80 | KDM4E (0.40) | POLBMAPTHPGDTSHRHSD17B10 | |
| SCHEMBL3099222 | 0.76 | GNRHR (0.37) | POLBMAPTHPGDTSHRHSD17B10 | |
| SCHEMBL3101526 | 0.75 | CYP11B1 (0.38) | — | |
| SCHEMBL3107457 | 0.73 | GAA (0.41) | POLBMAPTHPGDTSHRHSD17B10 | |
| SCHEMBL3110128 | 0.72 | MAOB (0.36) | POLBMAPTHPGDHSD17B10 | |
| SCHEMBL3109147 | 0.72 | CA12 (0.38) | MAPTHPGDTAS1R3TAS1R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2210876-B1 | HETEROCYCLIC COMPOUND AS GLUCAGON ANTAGONIST | TAKEDA PHARMACEUTICAL (JP) | 2015-05-20 | — | — | EP | disclosed |
| US-8309580-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-11-13 | — | — | US | disclosed |
| US-20100256156-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-10-07 | — | — | US | disclosed |
| EP-2210876-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2010-07-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256156-A1 | HETEROCYCLIC COMPOUND | GLP1R, GPR119, GCGR | POLB 4758/4885MAPT 4877/4885HPGD 1354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.